ORIENT-31 Regimen (Sintilimab Plus Bevacizumab Plus Platinum-doublet Chemotherapy) in Combination with Stereotactic Radiotherapy in EGFR-mutant Metastatic Non-small Cell Lung Cancer After First-line Third-generation EGFR Tyrosine Kinase Inhibitors (ORBIT Study)
Latest Information Update: 25 Jan 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Sintilimab (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ORBIT Study
- 21 Jan 2025 New trial record